HAVCR2 and acute myeloid leukemia: In order to evaluate the impact of HAVCR2 expression levels on clinical outcomes, AML patients were first divided into low and high expression groups based on the median HAVCR2 expression level, and the probability of 5-year OS was not significantly different between two groups (low versus high, 24.95% [95% CI 14.86%-36.39%] versus 24.54% [95% CI 13.59%-37.20%], p=0.6660) (Figure 4D).